ReviewBiomarkers From Blood and StoolBiomarkers of Inflammation in Inflammatory Bowel Disease
Section snippets
Serum and Blood Markers
The intense bowel inflammation of IBD is accompanied by an acute phase response detectable in the serum and blood. The acute phase response is characterized by increased elaboration of proteins involved in coagulation and fibrinolysis, such as fibrinogen, plasminogen, Factor VIII, and prothrombin; complement system components such as C1 inhibitor, C1s, C2, C3, C4, C5 and C9; proteinase inhibitors, including α-1-antitrypsin, α1 anti-chymotrypsin; transport proteins such as haptoglobin and
Stool Markers
As compared to blood or serum biomarkers, stool markers have the advantage of increased specificity for inflammatory processes localized to the bowel. While some fecal markers, such as α-1-antitrypsin and occult blood, reflect disruption of the mucosal barrier, such markers are not as accurate as others that are associated with the pathogenic inflammatory processes underlying IBD.13 Products of leukocyte degranulation, such as lysozyme, myeloperoxidase, eosinophilic cationic protein,
Urine Markers
A small number of substances excreted in urine have been investigated as biomarkers of inflammation in IBD. These include a variety of prostaglandin and leukotriene pathway products,18, 19, 20, 21 neutrophil gelatinase-associated lipocalin,22 alpha 1-acid-glycoprotein and Zn-alpha 2-glycoprotein,23 and neopterin.24 None is extensively validated, and none is in common use in the clinic.
Clinical Utility
Inflammation biomarkers may be useful in a variety of important clinical scenarios (see Figure 1 for applications of biomarkers of inflammation in CD). In the broadest sense, inflammation biomarkers have been used in IBD for 2 main purposes: (1) identifying patients with symptoms of IBD who should be further investigated for a possible IBD diagnosis; and (2) measuring or monitoring disease activity in response to induction or maintenance therapy. The latter purpose includes diverse settings,
Future Approaches
The search continues for more specific, sensitive, and responsive markers of inflammation to assist in the management of IBD. This effort has been accelerated by the recent availability of high-throughput discovery platforms, capable of measuring thousands of analytes simultaneously. These include gene expression arrays, and metabolomic and proteomic platforms.
Conclusions
Driven by a significant need in the clinic for accurate and noninvasive means to measure intestinal inflammation objectively, biomarkers of inflammation have been the subject of intense investigation in IBD. Increasingly, blood and stool markers such as CRP and calprotectin are being used in practice as measures of intestinal inflammation, with a growing understanding of their utility and limitations. Further studies are needed to improve understanding of these markers as surrogates for the
References (50)
- et al.
Biological markers in inflammatory bowel disease: Practical consideration for clinicians
Gastroenterologie Clinique Et Biologique
(2009) - et al.
Increased urinary F-2-isoprostanes in patients with Crohn's disease
American Journal of Gastroenterology
(2002) - et al.
Urine PGE-M: A metabolite of prostaglandin E-2 as a potential biomarker of advanced colorectal neoplasia
Clin Gastroenterol Hepatol
(2006) - et al.
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease
Clin Gastroenterol Hepatol
(2008) - et al.
Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission
Clin Gastroenterol Hepatol
(2014) - et al.
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy
Clin Gastroenterol Hepatol
(2012) - et al.
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis
J Crohns Colitis
(2012) - et al.
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed
Gastroenterology
(2014) - et al.
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial
Gastroenterology
(2007) - et al.
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Gut
(2014)
Infliximab for induction and maintenance therapy for ulcerative colitis
N Engl J Med
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Gut
Laboratory markers in ulcerative colitis: current insights and future advances
World J Gastrointest Pathophysiol
Adenosine deaminase activity in patients with Crohn's disease: distinction between active and nonactive disease
Eur J Gastroenterol Hepatol
Soluble ST2: a new and promising activity marker in ulcerative colitis
World J Gastroenterol
Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity
Inflamm Bowel Dis
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
Gut
Predicting outcome in severe ulcerative colitis
Gut
Genetic determinants of C-reactive protein
Curr Atheroscler Rep
C-reactive protein as a marker for inflammatory bowel disease
Inflamm Bowel Dis
Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage
Gut
Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation
Inflamm Bowel Dis
Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease
Aliment Pharmacol Ther
The role and utility of faecal markers in inflammatory bowel disease
Therap Adv Gastroenterol
The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis
J Crohns Colitis
Cited by (262)
Choosing the Right Therapy at the Right Time for Pediatric Inflammatory Bowel Disease: Does Sequence Matter
2023, Gastroenterology Clinics of North AmericaUpdates in the diagnosis and management of small-bowel Crohn's disease
2023, Best Practice and Research: Clinical Gastroenterology
Conflicts of interest The author discloses the following: received fees for consulting or speaking in CME programs received from AbbVie; Amgen; AstraZeneca; Avaxia Biologics; Bristol-Myers Squibb; Curatio CME Institute; Focus Medical Communications; Janssen Biotech; Millennium Pharmaceuticals/Takeda; Pfizer; Prometheus Laboratories; Puretech Ventures, LLC; Salix; Shire; Topivert Pharma; Luitpold Pharmaceuticals; MedImmune; Immune Pharmaceuticals; IMEDEX; Vindico Medical Education; Akros Pharma; Rockpointe; Strategic Consultants International; TiGenix; Celgene; research support from AbbVie; Amgen; AstraZeneca; Centers for Disease Control and Prevention; Crohn's & Colitis Foundation of America; Janssen Biotech; Millennium Pharmaceuticals/Takeda; Celgene; Pfizer; Prometheus Laboratories; and holds stock in Avaxia Biologics (non-publicly traded stock) and ETX Pharma (non-publicly traded stock).